img

Global Infliximab and Biosimilar Market Research Report 2024


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Infliximab and Biosimilar Market Research Report 2024

Infliximab (trade names Remicade among others) is a chimeric monoclonal antibody biologic drug that works against tumor necrosis factor alpha (TNF-α) and is used to treat autoimmune diseases.
According to Mr Accuracy reports new survey, global Infliximab and Biosimilar market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Infliximab and Biosimilar market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Infliximab and Biosimilar market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.



By Company


Janssen Biotech
Merck and Co.
Pfizer
Segment by Type
Infliximab
Infliximab-dyyb
Infliximab-abda

Segment by Application


Crohn's Disease
Pediatric Crohn's Disease
Ulcerative Colitis
Rheumatoid Arthritis
Ankylosing Spondylitis
Psoriatic Arthritis
Plaque Psoriasis

Consumption by Region


North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Infliximab and Biosimilar report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source

Table of Content

1 Infliximab and Biosimilar Market Overview
1.1 Product Overview and Scope of Infliximab and Biosimilar
1.2 Infliximab and Biosimilar Segment by Type
1.2.1 Global Infliximab and Biosimilar Market Value Comparison by Type (2024-2034)
1.2.2 Infliximab
1.2.3 Infliximab-dyyb
1.2.4 Infliximab-abda
1.3 Infliximab and Biosimilar Segment by Application
1.3.1 Global Infliximab and Biosimilar Market Value by Application: (2024-2034)
1.3.2 Crohn's Disease
1.3.3 Pediatric Crohn's Disease
1.3.4 Ulcerative Colitis
1.3.5 Rheumatoid Arthritis
1.3.6 Ankylosing Spondylitis
1.3.7 Psoriatic Arthritis
1.3.8 Plaque Psoriasis
1.4 Global Infliximab and Biosimilar Market Size Estimates and Forecasts
1.4.1 Global Infliximab and Biosimilar Revenue 2018-2029
1.4.2 Global Infliximab and Biosimilar Sales 2018-2029
1.4.3 Global Infliximab and Biosimilar Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Infliximab and Biosimilar Market Competition by Manufacturers
2.1 Global Infliximab and Biosimilar Sales Market Share by Manufacturers (2018-2024)
2.2 Global Infliximab and Biosimilar Revenue Market Share by Manufacturers (2018-2024)
2.3 Global Infliximab and Biosimilar Average Price by Manufacturers (2018-2024)
2.4 Global Infliximab and Biosimilar Industry Ranking 2021 VS 2022 VS 2024
2.5 Global Key Manufacturers of Infliximab and Biosimilar, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Infliximab and Biosimilar, Product Type & Application
2.7 Infliximab and Biosimilar Market Competitive Situation and Trends
2.7.1 Infliximab and Biosimilar Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Infliximab and Biosimilar Players Market Share by Revenue
2.7.3 Global Infliximab and Biosimilar Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Infliximab and Biosimilar Retrospective Market Scenario by Region
3.1 Global Infliximab and Biosimilar Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Infliximab and Biosimilar Global Infliximab and Biosimilar Sales by Region: 2018-2029
3.2.1 Global Infliximab and Biosimilar Sales by Region: 2018-2024
3.2.2 Global Infliximab and Biosimilar Sales by Region: 2024-2029
3.3 Global Infliximab and Biosimilar Global Infliximab and Biosimilar Revenue by Region: 2018-2029
3.3.1 Global Infliximab and Biosimilar Revenue by Region: 2018-2024
3.3.2 Global Infliximab and Biosimilar Revenue by Region: 2024-2029
3.4 North America Infliximab and Biosimilar Market Facts & Figures by Country
3.4.1 North America Infliximab and Biosimilar Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Infliximab and Biosimilar Sales by Country (2018-2029)
3.4.3 North America Infliximab and Biosimilar Revenue by Country (2018-2029)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Infliximab and Biosimilar Market Facts & Figures by Country
3.5.1 Europe Infliximab and Biosimilar Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Infliximab and Biosimilar Sales by Country (2018-2029)
3.5.3 Europe Infliximab and Biosimilar Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Infliximab and Biosimilar Market Facts & Figures by Country
3.6.1 Asia Pacific Infliximab and Biosimilar Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Infliximab and Biosimilar Sales by Country (2018-2029)
3.6.3 Asia Pacific Infliximab and Biosimilar Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Infliximab and Biosimilar Market Facts & Figures by Country
3.7.1 Latin America Infliximab and Biosimilar Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Infliximab and Biosimilar Sales by Country (2018-2029)
3.7.3 Latin America Infliximab and Biosimilar Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Infliximab and Biosimilar Market Facts & Figures by Country
3.8.1 Middle East and Africa Infliximab and Biosimilar Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Infliximab and Biosimilar Sales by Country (2018-2029)
3.8.3 Middle East and Africa Infliximab and Biosimilar Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Infliximab and Biosimilar Sales by Type (2018-2029)
4.1.1 Global Infliximab and Biosimilar Sales by Type (2018-2024)
4.1.2 Global Infliximab and Biosimilar Sales by Type (2024-2029)
4.1.3 Global Infliximab and Biosimilar Sales Market Share by Type (2018-2029)
4.2 Global Infliximab and Biosimilar Revenue by Type (2018-2029)
4.2.1 Global Infliximab and Biosimilar Revenue by Type (2018-2024)
4.2.2 Global Infliximab and Biosimilar Revenue by Type (2024-2029)
4.2.3 Global Infliximab and Biosimilar Revenue Market Share by Type (2018-2029)
4.3 Global Infliximab and Biosimilar Price by Type (2018-2029)
5 Segment by Application
5.1 Global Infliximab and Biosimilar Sales by Application (2018-2029)
5.1.1 Global Infliximab and Biosimilar Sales by Application (2018-2024)
5.1.2 Global Infliximab and Biosimilar Sales by Application (2024-2029)
5.1.3 Global Infliximab and Biosimilar Sales Market Share by Application (2018-2029)
5.2 Global Infliximab and Biosimilar Revenue by Application (2018-2029)
5.2.1 Global Infliximab and Biosimilar Revenue by Application (2018-2024)
5.2.2 Global Infliximab and Biosimilar Revenue by Application (2024-2029)
5.2.3 Global Infliximab and Biosimilar Revenue Market Share by Application (2018-2029)
5.3 Global Infliximab and Biosimilar Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Janssen Biotech
6.1.1 Janssen Biotech Corporation Information
6.1.2 Janssen Biotech Description and Business Overview
6.1.3 Janssen Biotech Infliximab and Biosimilar Sales, Revenue and Gross Margin (2018-2024)
6.1.4 Janssen Biotech Infliximab and Biosimilar Product Portfolio
6.1.5 Janssen Biotech Recent Developments/Updates
6.2 Merck and Co.
6.2.1 Merck and Co. Corporation Information
6.2.2 Merck and Co. Description and Business Overview
6.2.3 Merck and Co. Infliximab and Biosimilar Sales, Revenue and Gross Margin (2018-2024)
6.2.4 Merck and Co. Infliximab and Biosimilar Product Portfolio
6.2.5 Merck and Co. Recent Developments/Updates
6.3 Pfizer
6.3.1 Pfizer Corporation Information
6.3.2 Pfizer Description and Business Overview
6.3.3 Pfizer Infliximab and Biosimilar Sales, Revenue and Gross Margin (2018-2024)
6.3.4 Pfizer Infliximab and Biosimilar Product Portfolio
6.3.5 Pfizer Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Infliximab and Biosimilar Industry Chain Analysis
7.2 Infliximab and Biosimilar Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Infliximab and Biosimilar Production Mode & Process
7.4 Infliximab and Biosimilar Sales and Marketing
7.4.1 Infliximab and Biosimilar Sales Channels
7.4.2 Infliximab and Biosimilar Distributors
7.5 Infliximab and Biosimilar Customers
8 Infliximab and Biosimilar Market Dynamics
8.1 Infliximab and Biosimilar Industry Trends
8.2 Infliximab and Biosimilar Market Drivers
8.3 Infliximab and Biosimilar Market Challenges
8.4 Infliximab and Biosimilar Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Figure

List of Tables
Table 1. Global Infliximab and Biosimilar Market Value Comparison by Type (2024-2034) & (US$ Million)
Table 2. Global Infliximab and Biosimilar Market Value Comparison by Application (2024-2034) & (US$ Million)
Table 3. Global Infliximab and Biosimilar Market Competitive Situation by Manufacturers in 2022
Table 4. Global Infliximab and Biosimilar Sales (K Units) of Key Manufacturers (2018-2024)
Table 5. Global Infliximab and Biosimilar Sales Market Share by Manufacturers (2018-2024)
Table 6. Global Infliximab and Biosimilar Revenue (US$ Million) by Manufacturers (2018-2024)
Table 7. Global Infliximab and Biosimilar Revenue Share by Manufacturers (2018-2024)
Table 8. Global Market Infliximab and Biosimilar Average Price (USD/Unit) of Key Manufacturers (2018-2024)
Table 9. Global Key Players of Infliximab and Biosimilar, Industry Ranking, 2021 VS 2022 VS 2024
Table 10. Global Key Manufacturers of Infliximab and Biosimilar, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Infliximab and Biosimilar, Product Type & Application
Table 12. Global Key Manufacturers of Infliximab and Biosimilar, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Infliximab and Biosimilar by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Infliximab and Biosimilar as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Infliximab and Biosimilar Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 17. Global Infliximab and Biosimilar Sales by Region (2018-2024) & (K Units)
Table 18. Global Infliximab and Biosimilar Sales Market Share by Region (2018-2024)
Table 19. Global Infliximab and Biosimilar Sales by Region (2024-2029) & (K Units)
Table 20. Global Infliximab and Biosimilar Sales Market Share by Region (2024-2029)
Table 21. Global Infliximab and Biosimilar Revenue by Region (2018-2024) & (US$ Million)
Table 22. Global Infliximab and Biosimilar Revenue Market Share by Region (2018-2024)
Table 23. Global Infliximab and Biosimilar Revenue by Region (2024-2029) & (US$ Million)
Table 24. Global Infliximab and Biosimilar Revenue Market Share by Region (2024-2029)
Table 25. North America Infliximab and Biosimilar Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 26. North America Infliximab and Biosimilar Sales by Country (2018-2024) & (K Units)
Table 27. North America Infliximab and Biosimilar Sales by Country (2024-2029) & (K Units)
Table 28. North America Infliximab and Biosimilar Revenue by Country (2018-2024) & (US$ Million)
Table 29. North America Infliximab and Biosimilar Revenue by Country (2024-2029) & (US$ Million)
Table 30. Europe Infliximab and Biosimilar Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. Europe Infliximab and Biosimilar Sales by Country (2018-2024) & (K Units)
Table 32. Europe Infliximab and Biosimilar Sales by Country (2024-2029) & (K Units)
Table 33. Europe Infliximab and Biosimilar Revenue by Country (2018-2024) & (US$ Million)
Table 34. Europe Infliximab and Biosimilar Revenue by Country (2024-2029) & (US$ Million)
Table 35. Asia Pacific Infliximab and Biosimilar Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 36. Asia Pacific Infliximab and Biosimilar Sales by Region (2018-2024) & (K Units)
Table 37. Asia Pacific Infliximab and Biosimilar Sales by Region (2024-2029) & (K Units)
Table 38. Asia Pacific Infliximab and Biosimilar Revenue by Region (2018-2024) & (US$ Million)
Table 39. Asia Pacific Infliximab and Biosimilar Revenue by Region (2024-2029) & (US$ Million)
Table 40. Latin America Infliximab and Biosimilar Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 41. Latin America Infliximab and Biosimilar Sales by Country (2018-2024) & (K Units)
Table 42. Latin America Infliximab and Biosimilar Sales by Country (2024-2029) & (K Units)
Table 43. Latin America Infliximab and Biosimilar Revenue by Country (2018-2024) & (US$ Million)
Table 44. Latin America Infliximab and Biosimilar Revenue by Country (2024-2029) & (US$ Million)
Table 45. Middle East & Africa Infliximab and Biosimilar Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 46. Middle East & Africa Infliximab and Biosimilar Sales by Country (2018-2024) & (K Units)
Table 47. Middle East & Africa Infliximab and Biosimilar Sales by Country (2024-2029) & (K Units)
Table 48. Middle East & Africa Infliximab and Biosimilar Revenue by Country (2018-2024) & (US$ Million)
Table 49. Middle East & Africa Infliximab and Biosimilar Revenue by Country (2024-2029) & (US$ Million)
Table 50. Global Infliximab and Biosimilar Sales (K Units) by Type (2018-2024)
Table 51. Global Infliximab and Biosimilar Sales (K Units) by Type (2024-2029)
Table 52. Global Infliximab and Biosimilar Sales Market Share by Type (2018-2024)
Table 53. Global Infliximab and Biosimilar Sales Market Share by Type (2024-2029)
Table 54. Global Infliximab and Biosimilar Revenue (US$ Million) by Type (2018-2024)
Table 55. Global Infliximab and Biosimilar Revenue (US$ Million) by Type (2024-2029)
Table 56. Global Infliximab and Biosimilar Revenue Market Share by Type (2018-2024)
Table 57. Global Infliximab and Biosimilar Revenue Market Share by Type (2024-2029)
Table 58. Global Infliximab and Biosimilar Price (USD/Unit) by Type (2018-2024)
Table 59. Global Infliximab and Biosimilar Price (USD/Unit) by Type (2024-2029)
Table 60. Global Infliximab and Biosimilar Sales (K Units) by Application (2018-2024)
Table 61. Global Infliximab and Biosimilar Sales (K Units) by Application (2024-2029)
Table 62. Global Infliximab and Biosimilar Sales Market Share by Application (2018-2024)
Table 63. Global Infliximab and Biosimilar Sales Market Share by Application (2024-2029)
Table 64. Global Infliximab and Biosimilar Revenue (US$ Million) by Application (2018-2024)
Table 65. Global Infliximab and Biosimilar Revenue (US$ Million) by Application (2024-2029)
Table 66. Global Infliximab and Biosimilar Revenue Market Share by Application (2018-2024)
Table 67. Global Infliximab and Biosimilar Revenue Market Share by Application (2024-2029)
Table 68. Global Infliximab and Biosimilar Price (USD/Unit) by Application (2018-2024)
Table 69. Global Infliximab and Biosimilar Price (USD/Unit) by Application (2024-2029)
Table 70. Janssen Biotech Corporation Information
Table 71. Janssen Biotech Description and Business Overview
Table 72. Janssen Biotech Infliximab and Biosimilar Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 73. Janssen Biotech Infliximab and Biosimilar Product
Table 74. Janssen Biotech Recent Developments/Updates
Table 75. Merck and Co. Corporation Information
Table 76. Merck and Co. Description and Business Overview
Table 77. Merck and Co. Infliximab and Biosimilar Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 78. Merck and Co. Infliximab and Biosimilar Product
Table 79. Merck and Co. Recent Developments/Updates
Table 80. Pfizer Corporation Information
Table 81. Pfizer Description and Business Overview
Table 82. Pfizer Infliximab and Biosimilar Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 83. Pfizer Infliximab and Biosimilar Product
Table 84. Pfizer Recent Developments/Updates
Table 85. Key Raw Materials Lists
Table 86. Raw Materials Key Suppliers Lists
Table 87. Infliximab and Biosimilar Distributors List
Table 88. Infliximab and Biosimilar Customers List
Table 89. Infliximab and Biosimilar Market Trends
Table 90. Infliximab and Biosimilar Market Drivers
Table 91. Infliximab and Biosimilar Market Challenges
Table 92. Infliximab and Biosimilar Market Restraints
Table 93. Research Programs/Design for This Report
Table 94. Key Data Information from Secondary Sources
Table 95. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Infliximab and Biosimilar
Figure 2. Global Infliximab and Biosimilar Market Value Comparison by Type (2024-2034) & (US$ Million)
Figure 3. Global Infliximab and Biosimilar Market Share by Type in 2022 & 2029
Figure 4. Infliximab Product Picture
Figure 5. Infliximab-dyyb Product Picture
Figure 6. Infliximab-abda Product Picture
Figure 7. Global Infliximab and Biosimilar Market Value Comparison by Application (2024-2034) & (US$ Million)
Figure 8. Global Infliximab and Biosimilar Market Share by Application in 2022 & 2029
Figure 9. Crohn's Disease
Figure 10. Pediatric Crohn's Disease
Figure 11. Ulcerative Colitis
Figure 12. Rheumatoid Arthritis
Figure 13. Ankylosing Spondylitis
Figure 14. Psoriatic Arthritis
Figure 15. Plaque Psoriasis
Figure 16. Global Infliximab and Biosimilar Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 17. Global Infliximab and Biosimilar Market Size (2018-2029) & (US$ Million)
Figure 18. Global Infliximab and Biosimilar Sales (2018-2029) & (K Units)
Figure 19. Global Infliximab and Biosimilar Average Price (USD/Unit) & (2018-2029)
Figure 20. Infliximab and Biosimilar Report Years Considered
Figure 21. Infliximab and Biosimilar Sales Share by Manufacturers in 2022
Figure 22. Global Infliximab and Biosimilar Revenue Share by Manufacturers in 2022
Figure 23. The Global 5 and 10 Largest Infliximab and Biosimilar Players: Market Share by Revenue in 2022
Figure 24. Infliximab and Biosimilar Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 25. Global Infliximab and Biosimilar Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Figure 26. North America Infliximab and Biosimilar Sales Market Share by Country (2018-2029)
Figure 27. North America Infliximab and Biosimilar Revenue Market Share by Country (2018-2029)
Figure 28. U.S. Infliximab and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 29. Canada Infliximab and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 30. Europe Infliximab and Biosimilar Sales Market Share by Country (2018-2029)
Figure 31. Europe Infliximab and Biosimilar Revenue Market Share by Country (2018-2029)
Figure 32. Germany Infliximab and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 33. France Infliximab and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 34. U.K. Infliximab and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 35. Italy Infliximab and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 36. Russia Infliximab and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 37. Asia Pacific Infliximab and Biosimilar Sales Market Share by Region (2018-2029)
Figure 38. Asia Pacific Infliximab and Biosimilar Revenue Market Share by Region (2018-2029)
Figure 39. China Infliximab and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 40. Japan Infliximab and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 41. South Korea Infliximab and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 42. India Infliximab and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 43. Australia Infliximab and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 44. Taiwan Infliximab and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 45. Indonesia Infliximab and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 46. Thailand Infliximab and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 47. Malaysia Infliximab and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 48. Philippines Infliximab and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 49. Latin America Infliximab and Biosimilar Sales Market Share by Country (2018-2029)
Figure 50. Latin America Infliximab and Biosimilar Revenue Market Share by Country (2018-2029)
Figure 51. Mexico Infliximab and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 52. Brazil Infliximab and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 53. Argentina Infliximab and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 54. Middle East & Africa Infliximab and Biosimilar Sales Market Share by Country (2018-2029)
Figure 55. Middle East & Africa Infliximab and Biosimilar Revenue Market Share by Country (2018-2029)
Figure 56. Turkey Infliximab and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 57. Saudi Arabia Infliximab and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 58. UAE Infliximab and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 59. Global Sales Market Share of Infliximab and Biosimilar by Type (2018-2029)
Figure 60. Global Revenue Market Share of Infliximab and Biosimilar by Type (2018-2029)
Figure 61. Global Infliximab and Biosimilar Price (USD/Unit) by Type (2018-2029)
Figure 62. Global Sales Market Share of Infliximab and Biosimilar by Application (2018-2029)
Figure 63. Global Revenue Market Share of Infliximab and Biosimilar by Application (2018-2029)
Figure 64. Global Infliximab and Biosimilar Price (USD/Unit) by Application (2018-2029)
Figure 65. Infliximab and Biosimilar Value Chain
Figure 66. Infliximab and Biosimilar Production Process
Figure 67. Channels of Distribution (Direct Vs Distribution)
Figure 68. Distributors Profiles
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed